Boothbay Fund Management’s Regenxbio RGNX Stock Holding History

Boothbay Fund Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-303	Closed	-$1.01M	–	842
2017 Q4	$1.01M	Buy	+303	New	+$9.13K	0.15%	128

Other funds holding RGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

WS Management Jacksonville, Florida $1.13B AUM 53.44% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Boothbay Fund Management's RGNX Position: Q2 2018 in Review

Boothbay Fund Management sold out of Regenxbio (RGNX) in Q2 2018, closing a stake of 8,868 shares — an estimated $265K sold.

Boothbay Fund Management first reported a position in RGNX in Q1 2018 and held it in 1 quarter. The position peaked at $265K in Q1 2018. 177 funds tracked by Wall St. Rank hold RGNX as of Q2 2018.

Boothbay Fund Management reported no remaining Regenxbio position as of Q2 2018 after selling out during the quarter.
Boothbay Fund Management sold 8,868 Regenxbio shares in Q2 2018, an estimated $265K.
Boothbay Fund Management first reported a position in Regenxbio in Q1 2018 and held it in 1 quarter.
Boothbay Fund Management's Regenxbio position peaked at $265K in Q1 2018.
177 funds tracked by Wall St. Rank held Regenxbio as of Q2 2018.

Based on Boothbay Fund Management's 13F filing for Q2 2018, filed 14 Aug 2018.